Seer Inc
Change company Symbol lookup
Select an option...
SEER Seer Inc
ITCI Intra-Cellular Therapies Inc
VZ Verizon Communications Inc
TISI Team Inc
PRTK Paratek Pharmaceuticals Inc
KIRY Kiewit Royalty Trust
OCAXW OCA Acquisition Equity Warrant Exp 14 Jan 2026 *W EXP 01/31/2028
ABBV Abbvie Inc
IIIN Insteel Industries Inc
KO Coca-Cola Co
Go

Company profile

Seer, Inc. is a life sciences technology company. The Company enables scientific outcomes by commercializing products for researchers to unlock biological information. Its initial product, the Proteograph Product Suite (Proteograph), uses its engineered nanoparticle (NP) technology to provide access across the proteome. Its Proteograph Product Suite is comprised of consumables, an automation instrument and software. Its Proteograph provides a workflow, which enables proteomic profiling and the analysis of samples needed to characterize the nature of the proteome. The Company’s Proteograph consumables consist of its NP panel and other consumables necessary to assay samples on its SP100 automation instrument. Its SP100 automation instrument is custom-configured liquid handling workstation. The Company's Proteograph Instrument Control Software (PICS) for the SP100 instrument is fixed and designed to its specified workflow.

Closing Price
$25.17
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
0

10-day average volume:
517,492
0

FINAL DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Longeveron Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

11:55 pm ET November 14, 2021 (Accesswire) Print

LOS ANGELES, CA / ACCESSWIRE / November, 14 2021 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Longeveron Inc. ("Longeveron" or "the Company") (NASDAQ:LGVN) for violations of the federal securities laws.

Image: https://s.yimg.com/it/api/res/1.2/zBI9DMcawbvxUmnXOluesQ--~A/YXBwaWQ9eW5ld3M7c209MTt3PTgwMDtpbD1wbGFuZQ--/https://www.accesswire.com/users/newswire/images/549354/shaw%20law%20logo.png.cf.jpg

Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted on February 12, 2021 (the "IPO"), or between February 12, 2021 and August 12, 2021, inclusive (the "Class Period"), are encouraged to contact the firm before November 12, 2021.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Longeveron's cell-based therapy product, Lomecel-B, did not demonstrate the effectiveness in treating aging frailty that it had touted to investors. The Company overstated the commercial prospects of Lomecel-B. Based on these facts, the Company's claims were false and materially misleading throughout the IPO and class period. When the market learned the truth about Longeveron, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm

Brian Schall, Esq.,

www.schallfirm.com

Office: 310-301-3335

info@schallfirm.com

SOURCE: The Schall Law Firm

View source version on accesswire.com:

https://www.accesswire.com/672814/FINAL-DEADLINE-TOMORROW-The-Schall-Law-Firm-Announces-the-Filing-of-a-Class-Action-Lawsuit-Against-Longeveron-Inc-and-Encourages-Investors-with-Losses-in-Excess-of-100000-to-Contact-the-Firm

comtex tracking

COMTEX_396942800/2457/2021-11-14T23:55:41

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.